Market Overview

UPDATE: Maxim Group Initiates Threshold Pharmaceuticals at Buy on Doxorubicin Potential

Share:
Related THLD
19 Lesser-Known Biotech Stocks With Robust Drug Pipelines
Threshold Pharmaceuticals Receives FDA Fast Track Designation For TH-302 For The Treatment Of Previously Untreated Patients With Metastatic Or Locally Advanced Unresectable Soft Tissue Sarcoma
Threshold Pharmaceuticals Just Turned Up the Heat (AEMD, THLD, AMDA) (Small Cap Network)

Maxim Group initiated coverage on Threshold Pharmaceuticals (NASDAQ: THLD) with a Buy rating and a price target of $10 per share.

Maxim Group commented, "THLD's lead drug, TH-302, is currently in a phase III trial as a first-line treatment with doxorubicin for advanced soft tissue sarcoma (STS) and at the end of a phase IIb trial as a first-line therapy with gemcitabine for pancreatic cancer. Both cancers are difficult-to-treat malignancies with limited chemotherapies on the market. Based on earlier trial results, we believe there is a good chance for THLD to deliver significant improvement of overall survival (OS) in expanded patient populations."

Threshold Pharmaceuticals closed at $7.78 on Wednesday.

Latest Ratings for THLD

DateFirmActionFromTo
Sep 2014Cantor FitzgeraldInitiates Coverage onBuy
Sep 2014HC WainwrightInitiates Coverage onBuy
Feb 2013Piper JaffrayUpgradesNeutralOverweight

View More Analyst Ratings for THLD
View the Latest Analyst Ratings

Posted-In: Maxim GroupAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (THLD)

Around the Web, We're Loving...

Get Benzinga's Newsletters